Tetracyclic inhibitors of fatty acid amide hydrolase

A compound of Formula (I):

• wherein
• R1 is H;
• R2 is pyridyl optionally substituted with Rx;
• or R1 and R2 taken together with the oxazole to which they are attached form oxazolo[4,5-b]pyridin-2-yl;
• where Rx is —C1-6alkyl;
• —C3-6cycloalkyl;
• —CF3;
• —CN;
• —C(O)C1-4alkyl optionally substituted with one, two, or three fluoro substituents;
• —CO2C1-4alkyl;
• —CO2H;
• —C(O)N(Ra)Rb;
• —OH;
• —OC1-6alkyl;
• halo;
• —NO2;
• —NRaRb;
• —N(Ra)C(O)Rb;
• —N(Ra)SO2Rb;
• —SO2N(Ra)Rb;
• —S(O)0-2Rf;
• or tetrazolyl;
• where Ra and Rb are each independently —H, —C1-6alkyl, or —C3-6cycloalkyl;
• and Rf is —C1-4alkyl optionally substituted with one, two, or three fluoro substituents;
• R3 is —H;
• —C1-6alkyl;
• C3-6cycloalkyl;
• —CF3;
• —CN;
• —C(O)C1-4alkyl optionally substituted with one, two, or three fluoro substituents;
• —CO2C1-4alkyl;
• —CO2H;
• —C(O)N(Rc)Rd;
• —OH;
• —OC1-6alkyl;
• -halo;
• —NO2;
• —NRcRd;
• —N(Rc)C(O)Rd;
• —N(Rc)SO2Rd;
• —SO2N(Rc)Rd;
• —S(O)0-2Rf;
• or —CH2N(Rg)Rh;
• where Rc and Rd are each independently —H, —C1-6alkyl, or —C3-6cycloalkyl;
• Rf is —C1-4alkyl optionally substituted with one, two, or three fluoro substituents;
• and
• Rg and Rh are each independently H or C1-4alkyl;
• or Rg and Rh taken together with the nitrogen to which they are attached form a monocyclic saturated heterocycloalkyl group;
• X is —CH2—, —O—, —S—, —S(O)—, —S(O)2—, —N(Ri)—, or —CH(OH)—;
• and
• Y is absent or is —CH2—, —O—, —S—, —S(O)—, —S(O)2—, —NRi—, —CH2O—, or —OCH2—;
• wherein Ri is —H or —C1-6alkyl;
• and provided that when Y is absent, a single bond is present between the two phenyl rings of formula I;
• a pharmaceutically acceptable salt of a compound of Formula (I), a pharmaceutically acceptable prodrug of a compound of Formula (I), or a pharmaceutically active metabolite of a compound of Formula (I).